BACKGROUND: Mutations in the PIK3CA gene (phosphoinositide-3-kinase, catalytic, alpha polypeptide) have recently been described in a number of cancers, and their detection is currently limited because of the low sensitivity of conventional sequencing techniques. METHODS: We combined Amplification Refractory Mutation System (ARMS; AstraZeneca) allele-specific PCR and Scorpions (DxS) to develop assays for tumor-borne PIK3CA mutations and used real-time PCR to develop high-throughput multiplexed assays for the most commonly reported PIK3CA mutants (H1047L, H1047R, E542K, E545K). RESULTS: These assays were more sensitive than sequencing and could detect 5 copies of mutant DNA in proportions as low as 0.1% of the total DNA. We assayed DNA extracted from human tumors and detected PIK3CA mutation frequencies of 10.2% in colorectal cancer, 38.7% in breast cancer, 1.9% in lung cancer, and 2.9% in melanoma. In contrast, sequencing detected only 53% of the mutations detected by our assay. CONCLUSIONS: Multiplexed assays, which can easily be applied to clinical samples, have been developed for the detection of PIK3CA mutations.
BACKGROUND: Mutations in the PIK3CA gene (phosphoinositide-3-kinase, catalytic, alpha polypeptide) have recently been described in a number of cancers, and their detection is currently limited because of the low sensitivity of conventional sequencing techniques. METHODS: We combined Amplification Refractory Mutation System (ARMS; AstraZeneca) allele-specific PCR and Scorpions (DxS) to develop assays for tumor-borne PIK3CA mutations and used real-time PCR to develop high-throughput multiplexed assays for the most commonly reported PIK3CA mutants (H1047L, H1047R, E542K, E545K). RESULTS: These assays were more sensitive than sequencing and could detect 5 copies of mutant DNA in proportions as low as 0.1% of the total DNA. We assayed DNA extracted from humantumors and detected PIK3CA mutation frequencies of 10.2% in colorectal cancer, 38.7% in breast cancer, 1.9% in lung cancer, and 2.9% in melanoma. In contrast, sequencing detected only 53% of the mutations detected by our assay. CONCLUSIONS: Multiplexed assays, which can easily be applied to clinical samples, have been developed for the detection of PIK3CA mutations.
Authors: Michaela J Higgins; Danijela Jelovac; Evan Barnathan; Brian Blair; Shannon Slater; Penny Powers; Jane Zorzi; Stacie C Jeter; George R Oliver; John Fetting; Leisha Emens; Carol Riley; Vered Stearns; Frank Diehl; Philipp Angenendt; Peng Huang; Leslie Cope; Pedram Argani; Kathleen M Murphy; Kurtis E Bachman; Joel Greshock; Antonio C Wolff; Ben H Park Journal: Clin Cancer Res Date: 2012-03-15 Impact factor: 12.531
Authors: Marta Herreros-Villanueva; Noemí Gomez-Manero; Pilar Muñiz; Carlos García-Girón; Maria Jesús Coma del Corral Journal: Mol Biol Rep Date: 2010-06-23 Impact factor: 2.316
Authors: Yan Ye; Qun Li; Wang Lai Hu; Hsin-Yi Tseng; Lei Jin; Xu Dong Zhang; Lin Jie Zhang; Sen Yang Journal: Transl Oncol Date: 2013-08-01 Impact factor: 4.243
Authors: Helen Schneck; Christina Blassl; Franziska Meier-Stiegen; Rui Pedro Neves; Wolfgang Janni; Tanja Fehm; Hans Neubauer Journal: Mol Oncol Date: 2013-07-13 Impact factor: 6.603
Authors: Vandana G Abramson; M Cooper Lloyd; Tarah Ballinger; Melinda E Sanders; Liping Du; Darson Lai; Zengliu Su; Ingrid Mayer; Mia Levy; Delecia R LaFrance; Cindy L Vnencak-Jones; Yu Shyr; Kimberly B Dahlman; William Pao; Carlos L Arteaga Journal: Breast Cancer Res Treat Date: 2014-04-11 Impact factor: 4.872